Genprex begins dosing of phase 1/2 trial of REQORSA, Tagrisso combo
Genprex has dosed the first patient in the Acclaim-1 phase 1/2 clinical trial of REQORSA immunogene therapy candidate in combination with Tagrisso (osimertinib) in a ... Read More
AstraZeneca gets FDA approval for Tagrisso for type of NSCLC
AstraZeneca has secured extended approval from the US Food and Drug Administration for using Tagrisso (osimertinib) as an adjuvant treatment of non-small cell lung cancer ... Read More